Investigation of the stereoselectivity of an anti-amino acid antibody using molecular modeling and ligand docking

Chirality

Volumn 20, Issue 3-4, 2008, Pages 559-570

  Ranieri, Daniel I ^a   Corgliano, Danielle M ^a   Franco, Elliott J ^a   Hofstetter, Heike ^a   Hofstetter, Oliver ^a  

^a NORTHERN ILLINOIS UNIVERSITY   (United States)

Author keywords

Anti hapten antibody; Antibody stereoselectivity; Computer modeling; Fluorescence enhancement; Ligand docking; Protein ligand interaction

Indexed keywords

AMINO ACID; ANTIBODY; AROMATIC AMINO ACID; NORVALINE; PHENYLALANINE; TRYPTOPHAN; TYROSINE;

ARTICLE; BINDING SITE; COMPLEX FORMATION; ENANTIOMER; FLUORESCENCE SPECTROSCOPY; HYDROGEN BOND; HYDROPHOBICITY; LIGAND BINDING; MOLECULAR INTERACTION; MOLECULAR MODEL; PRIORITY JOURNAL; STEREOCHEMISTRY; STEREOSPECIFICITY;

AMINO ACID SEQUENCE; AMINO ACIDS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY COMPLEX; ANTIGEN-ANTIBODY REACTIONS; BINDING SITES, ANTIBODY; COMPUTER SIMULATION; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; LIGANDS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; STEREOISOMERISM;

EID: 39749114973     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.20522     Document Type: Article

References (88)

1. Fischer E. Einfluss der configuration auf die Wirkung der enzyme. Ber Dtsch Chem Ges 1894;27:2985-2993.
2. Cushny AR. Atropine and the hyoscyamines - a study of the action of optical isomers. J Physiol 1904:176-194.
3. Landsteiner K, van der Scheer J. Serological differentiation of steric isomers. J Exp Med 1928;48:315-320.
4. Holmstedt B. The use of enantiomers in biological studies: an historical review. In: Holmstedt B, Frank H, Testa B, editors. Chirality and biological activity. New York: Alan R. Liss; 1990. p 1-14.
5. Eichelbaum M, Gross AS. Stereochemical aspects of drug action and disposition. Adv Drug Res 1996;28:1-64.
6. Soudijn W, van Wijngaarden I, IJzerman AP. Stereoselectivity of drug-receptor interactions. IDrugs 2003;6:43-56.
7. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. FDA's policy statement for the development of new stereoisomeric drugs. 5/1/92, corrections made 1/3/97; http://www.fca.gov/cder/guidance/stereo. htm.
8. Jones BJ, Desantis G. Towards understanding and tailoring the specificity of synthetically useful enzymes. Acc Chem Res 1999;32:99-107
9. Heine A, Stura EA, Yli-Kaulhaluoma J, Gao C, Deng S, Beno BR, Houk KN, Janda KD, Wilson IA. An antibody exo diels-alderase inhibitor complex at 1.95 Å resolution. Science 1998;279:1934-1940.
10. Easson LH, Stedman E. Studies on the relationship between chemical constitution and physiological action. V. Molecular dissymmetry and physiological activity. Biochem J 1933;27:1257-1266.
11. Ogston AG. Interpretation of experiments on metabolic processes, using isotopic tracer elements. Nature 1948;162:963.
12. Fersht A. Structure and mechanism in protein science: a guide to enzyme catalysis and protein folding. New York: W. H. Freeman; 1999, Fourth Printing 2002. p 324-348.
13. Van Oss CJ. Nature of specific ligand-receptor bonds, in particular the antigen-antibody bond. In: van Oss CJ, van Regenmortel MHV, editors. Immunochemistry. New York: Marcel Dekker; 1994. p 581-614
14. Mesecar AD, Koshland DE Jr. A new model for protein stereospecificity. Nature 2000;403:614-615.
15. Sundaresan V, Abrol R. Towards a general model for protein-substrae stereoselectivity. Protein Sci 2002;11:1330-1339.
16. Ståhlberg J, Henrikson H, Divne C, Isaksson R, Pettersson G, Johansson G, Jones TA. Structural basis for enantiomer binding and separation of a common β-blocker: crystal structure of cellobiohydrolase Cel7A with bound (S)-propanolol at 1.9 Å resolution. J Mol Biol 2001;305:79-93.
17. Lamzin VS, Dauter Z, Wilson KS. How nature deals with stereoisomers. Curr Opin Struct Biol 1995;5:830-836.
18. Kallio P, Sultana A, Niemi J, Mäntsälä P, Schneider G. Crystal structure of the polyketide cyclase AknH with bound substrate and product analogue: implications for catalytic mechanism and product stereoselectivity. J Mol Biol 2006;357:210-220.
19. Petitpas I, Bhattacharya AA, Twine S, East M, Curry S. Crystal structure analysis of warfarin binding to human serum albumin. J Biol Chem 2001;76:22804-22809.
20. D'Souza LJ, Gigant B, Knossow M, Green BS. Remarkable remote chiral recognition in a reaction mediated by a catalytic antibody. J Am Chem Soc 2002;124:2114-2115.
21. Parkkinen T, Nevanen TK, Koivula A, Rouvinen J. Crystal structures of an enantioselective Fab-fragment in free and complex forms. J Mol Biol 2006;357:471-480.
22. Pinkerton TC, Howe WJ, Ulrich EL, Comiskey JP, Haginaka J, Murashima T, Walkenhorst WF, Westler W, Markley JL. Protein binding chiral discrimination of HPLC stationary phases made with whole, fragmented, and third domain turkey ovomucoid. Anal Chem 1995;67:2354-2367.
23. Canizzarro CE, Shley JA, Janda KD, Houk KN. Experimental determination of the absolute enantioselectivity of an antibody-catalyzed Diels-Alder reaction and theoretical explorations of the origins of stereoselectivity. J Am Chem Soc 2003;125:2489-2506.
24. Lavecchia A, Cosconati S, Novellino E, Calleri E, Temporini C, Massolini G, Carbonara G, Fracchiolla G, Loidice F. Exploring the molecular basis of the enantioselective binding of penicillin G acylase towards a series of 2-aryloxyalcanoic acids: a docking and molecular dynamics study. J Mol Graph Model 2007;25:773-783.
25. De Jong RM, Kalk KH, Tang L, Janssen DB, Dijkstra BW. The X-ray strycture of the haloalcohol dehalogenase HheA from Anthrobacter sp. strain AD2: insight into enantioselectivity and halide binding in the haloalcohol dehalogenase family. J Bacteriol 2006;188:4051-4056.
26. Nevanen TK, Hellman M-L, Munck N, Wohlfahrt G, Koivula A, Söderlund H. Model-based mutagenesis to improve the enantioselective fractionation properties of an antibody. Protein Eng 2003;16:1098-1097.
27. Zhu X, Tanaka F, Hu Y, Heine A, Fuller R, Zhong G, Olson AJ, Lerner RA, Barbas CF III, Wilson IA. The origin of enantioselecitivity in aldolase antibodies: Crystal structure, site-directed mutagenesis, and computational analysis. J Mol Biol 2004;343:1269-1280.
28. Henke E, Bornscheuer UT, Schmid RD, Pleiss J. A molecular mechanism of enantiorecognition of tertiary alcohols by carboxylesterases. ChemBioChem 2003;4:485-493.
29. Feenstra KA, Hofstetter K, Bosch R, Schmid A, Commandeur JNM, Vermeulen NPE. Enantioselective substrate binding in a monooxygenase protein model by molecular dynamics and docking. Biophys J 2006;91:3206-3216.
30. Hofstetter O, Hofstetter H, Wilchek M, Schurig V, Green BS. Production and applications of antibodies directed against the chiral center of α-amino acids. Int J Bio Chromatogr 2000;5:165-174.
31. Hofstetter O, Lindstrom H, Hofstetter H. Direct resolution of enantiomers in high-performance immunoaffinity chromatography under isocratic conditions. Anal Chem 2002;74:2119-2125.
32. Dutta P, Tipple CA, Lavrik NV, Datskos PG, Hofstetter H, Hofstetter O, Sepaniak MJ. Enantioselective sensors based on antibody-mediated nanomechanics. Anal Chem 2003;75:2342-2348.
33. Tsourkas A, Hofstetter O, Hofstetter H, Weissleder R, Josephson L. Magnetic relaxation switch immunosensors detect enantiomeric impurities. Angew Chem Int Ed Engl 2004;43:2395-2399.
34. Hofstetter O, Lindstrom H, Hofstetter H. The effect of the mobile phase on antibody-based enantiomer separations of amino acids in high-performance liquid chromatography. J Chromatogr A 2004;1024:85-95.
35. Hofstetter H, Cary JR, Eleniste PP, Hertweck JK, Lindstrom HJ, Ranieri DI, Smith GB, Undesser LP, Zeleke JM, Zeleke TK, Hofstetter O. New developments in the production and use of stereoselective antibodies. Chirality 2005;17:S9-S18.
36. Hofstetter O, Hertweck JK, Hofstetter H. Detection of enantiomeric impurities in a simple membrane-based optical immunosensor. J Biochem Biophys Methods 2005;63:91-99.
37. Zeleke TK, Zeleke JM, Hofstetter H, Hofstetter O. Stereoselective antibodies to free α-hydroxy acids. J Mol Recogn 2005;18:334-340.
38. Zeleke JM, Smith GB, Hofstetter H, Hofstetter O. Enantiomer separation of amino acids in immunoaffinity micro LC-MS. Chirality 2006;18:544-550.
39. Zhang S, Ding J, Liu Y, Kong J, Hofstetter O. Development of a highly enantioselective capacitive immunosensor for the detection of alpha-amino acids. Anal Chem 2006;78:7592-7596.
40. Wang Z, Raifu M, Howard M, Smith L, Hansen D, Goldsby R, Ratner D. Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3′ to 5′ exonuclease activity. J Immunol Methods 2000;233:167-177.
41. EXPAsy Proteomics Server, http://ca.expasy.org/, accessed 03/07.
42. NCBI BLAST. http://www.ncbi.nlm.nih.gov/BLAST/, accessed 03/07, Standard Nucleotide BLAST [blastn], nr Database.
43. Berman MH, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucleic Acids Res 2000;28:235-242.
44. Web Antibody Modeling. http://antibody.bath.ac.uk/, accessed 03/07.
45. Whitelegg NRJ, Rees AR. WAM - an improved algorithm for modelling antibodies on the web. Protein Eng 2000;13:819-824.
46. WAMpredict. https://antibody.bath.ac.uk/WAMpredict.html, accessed 03/07.
47. SWISS MODEL. http://swissmodel.expasy.org/, accessed 03/07.
48. Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res 2003;31:3381-3385.
49. Vasudevan S, Tsuruo T, Rose DR. Mode of binding of anti-P-glycoprotein antibody MRK-16 to its antigen. A crystallographic and molecular modeling study. J Biol Chem 1998;273:25413-25419.
50. Oomen CJ, Hoogerhout P, Kuipers B, Vidarsson G, Van Alphen L, Gros P. Crystal structure of an anti-meningococcal subtype P1.4 pora antibody provides basis for peptide-vaccine design. J Mol Biol 2005;351:1070-1080.
51. Deep-View, http://www.usm.maine.edu/spdbv/, accessed 03/07.
52. Melo F, Feytmans E. Assessing protein structures with a non-local atomic interaction energy. J Mol Biol 1998;277:1141-1152. http://protein.bio.puc.cl/ cardex/servers/anolea/index.html
53. van Gunsteren WF, Billeter SR, Eising A, Hünenberger PH, Krüger P, Mark AE, Scott WRP, Tironi IG. Biomolecular simulations: the GROMOS96 manual and user guide. 1996 VdF Hochschulverlag ETHZ, Zürich.
54. Luthy R, Bowie JU, Eisenberg D. Assessment of protein models with three-dimensional profiles. Nature 1992;356:83-85. http://nihserver.mbi.ucla. edu/Verify_3D/
55. Dundee PRODRG2 Server. http://davapcl.bioch.dundee.ac.uk/programs/prodrg/ prodrg.html, accessed 03/07.
56. Schuettelkopf AW, Van Aalten DMF. PRODRG - a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D 2004;60:1355-1363.
57. Pople JA, Head-Gordon M, Fox DJ, Raghavachari K, Curtiss LA. Gaussian-1 theory: a general procedure for prediction of molecular-energies. J Chem Phys 1989;90:5622-5629. http://www.gaussian.com/gv_plat.htm
58. Krammer A, Kirchhoff PD, Jiang X, Venkatachalam CM, Waldman M. LigScore: a novel scoring function for predicting binding affinities. J Mol Graph Model 2005;23:395-407.
59. Gehlhaar DK, Verkhivker GM, Rejto PA, Sherman CJ, Fogel DB, Fogel LJ, Freer ST. Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformational flexible docking by evolutionary programming. Chem Biol 1995;2:317-324.
60. Gehlhaar DK, Bouzida D, Rejto PA. Rational drug design: novel methodology and practical applications. Am Chem Soc ACS Symp Ser 1999;719:292-311.
61. Jain AN. Scoring non-covalent ligand-protein interactions: a continuous differentiable function turned to compute binding affinitites. J Comput Aided Mol Des 1996;10:427-440.
62. Muegge I, Martin YC. A general and fast scoring function for protein-ligand interaction: a simplified potential approach. J Med Chem 1999;42:791-804.
63. Böhm H-J. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J Comput Aided Mol Des 1994;8:243-256.
64. Böhm H-J, Stahl M. Rapid empirical scoring functions in virtual screening applications. Med Chem Res 1999;9:445-462.
65. Mpamhanga CP, Chen B, McLay IM, Ormsby DL, Lindvall MK. Retrospective docking study of PDE4B ligands and an analysis of the behavior of selected scoring functions. Chem Inf Model 2005;45:1061-1074.
66. Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 1995;8:127-134.
67. Landsteiner K. The specificity of serological reactions. New York: Dover; 1962.
68. Hofstetter O, Hofstetter H, Schurig V, Wilchek M, Green BS. Antibodies can recognize the chiral center of free α-amino acids. J Am Chem Soc 1998;120:3251-3252.
69. Wu T, Kabat EA. An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J Exp Med 1970;132:211-250.
70. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. Sequences of proteins of immunological interest, 5th ed. NIH Publication No. 91-3242 U.S. Department of Health and Human Services; 1991.
71. Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, Sheriff S, Padlan EA, Davies D, Tulip WR, Colman PM, Spinelli S, Alzari PM, Poljak RJ. Conformations of immunoglobulin hypervariable regions. Nature 1989;342:877-883.
72. Martin ACR, Cheetham JC, Rees AR. Molecular modelling of antibody combining sites. Methods Enzymol 1991;203:121-153.
73. Honegger A, Plückthun A. Yet another numbering scheme for immunoglobulin variable domains: an automated modeling and analysis tool. J Mol Biol 2001;309:657-670.
74. Pedersen JT, Henry AH, Searle SMJ, Guild BC, Roguska M, Rees AR. Comparison of surface accessible residues in human and murine immunoglobulin Fv domains implication for humanization of murine antibodies. J Mol Biol 1994;235:959-973.
75. Foote J, Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol 1992;224:487-499.
76. Martin ACR, Cheetham JC, Rees AR. Modelling antibody hypervariable loops: a combined algorithm. Proc Natl Acad Sci USA 1989;86:9268-9272.
77. Dauber-Osguthorpe P, Roberts VA, Osguthorpe DJ, Wolff J, Genest M, Hagler AT. Structure and energetics of ligand-binding to proteins: Eschericia coli dihydrofolate reductase/trimethoprim, a drug-receptor system. Proteins 1988;4:31-47.
78. Wilson IA, Stanfield RL. Antibody-antigen interactions: new structures and new conformational changes. Curr Opin Struct Biol 1994;4:857-867.
79. Tovchigrechko A, Wells CA, Vakser IA. Docking of protein models. Protein Sci 2002;11:1888-1896.
80. Najmanovich R, Kuttner J, Sobolev V, Edelman M. Side-chain flexibility in proteins upon ligand binding. Proteins: Struct Funct Genet 2000;39:261-268.
81. Samanta U, Pal D, Chakrabarti P. Packing of aromatic rings against tryptophan residues in proteins. Acta Crystallogr D 1999;55:1421-1427.
82. Böhm H-J. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J Comp Aided Mol Des 1994:8:243-256.
83. Böhm H-J. Prediction of binding constants of protein ligands: a Eist method for the prioritization of hits obtained from the de novo design or 3D database search programs. J Comp Aided Mol Des 1998;12:309-323.
84. Ward LD. Measurement of ligand binding to proteins by fluorescence spectroscopy. Methods Enzymol 1985;117:400-414.
85. Murzin AG, Brenner SE, Hubbard T, Chothia C. SCOP: a structural classification of proteins database for the investigation of sequences and structures. J Mol Biol 1995;247:536-540.
86. Salem GM, Hutchinson EG, Orengo CA, Thornton JM. Correlation of observed fold frequency with the occurrence of local structural motifs. J Mol Biol 1999;287:969-981.
87. Rini JM, Schulze-Gahmen U, Wilson IA. Structural evidence for induced fit as a mechanism for antibody-antigen recognition. Science 1992;255:959-965.
88. Wilson IA, Stanfield RL. Antibody-antigen interactions. Curr Opin Struct Biol 1993;3:113-118.